ILiAD Biotechnologies Announces Presentation at the 2023 World Vaccine Congress in Barcelona
ILiAD Biotechnologies says it hit a homer in a whooping cough vaccine challenge trial. The biotech linked its nasal vaccine to protection against colonization by the pathogen, causing the phase 2b study to meet its primary endpoint in the per-protocol population.
ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonization in Phase 2b Human Challenge Study of BPZE1 Vaccine
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a vaccine company utilizing its B-Tech™ technology to develop novel vaccines against infectious diseases, today announced that Chief Medical Officer Stephanie Noviello, MD, MPH, will present information regarding its pertussis vaccine, BPZE1, at the World Vaccine Congress in Washington, DC (April 3 – 6, 2023). nnBPZE1 is the most advanced next generation pertussis vaccine, designed to overcome deficiencies of current vaccines, including limited durability and the inability to prevent nasopharyngeal Bordetella pertussis infections that lead to transmission, especially to vulnerable infants. BPZE1 has successfully completed four human clinical studies and has received FDA Fast Track designation. nnDr. Noviello will overview results from the BPZE1 Phase 2b clinical trial in healthy adults that were published in The Lancet (March 2023) and highlight the study designs of the ongoing Phase 2b Human Challenge study and Phase 2b School-age study. nnPresentation details: nnLocation: Walter E. Washington Convention Center nPresentation Date/Time: Thursday, April 6, 2023 at 10:25 a.m. ET nTitle: Live Attenuated Pertussis Intranasal Vaccine (BPZE1) nSpeaker: Stephanie Noviello, MD, MPH, Chief Medical Officer at ILiAD Biotechnologies nnA copy of the presentation will be available after the conclusion of the meeting in the “BPZE1 Publications” section of the ILiAD website. nnAbout Pertussis nnPertussis (whooping cough) is a potentially life-threatening disease caused by the highly contagious respiratory bacterium, Bordetella pertussis. According to U.S. Centers for Disease Control and Prevention, pertussis affects approximately 16 million people each year globally, accounting for nearly 200,000 deaths. There has been an overall increase in reported pertussis cases since the early 1980s. Pertussis is highly contagious and an infected person can transmit B. pertussis to as many as 15 other people. Pertussis can lead to serious illness in people of all ages and can be life-threatening in young infants. nnAbout BPZE1 nnBPZE1 is the only next generation live-attenuated intranasal pertussis vaccine in advanced clinical trials designed to protect against Bordetella pertussis nasal infection (colonization) and active disease through the induction of broad and sustained mucosal and systemic immunity. BPZE1 is currently being developed as a booster vaccine with future development investigating its application as a primary vaccination in infants.
ILiAD Biotechnologies Announces Publication of BPZE1 Adult Phase 2b Clinical Results in The Lancet
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most advanced next generation pertussis vaccine, today announced the closing of a $42.8 million Class D round of financing. These funds will enable the company to conduct a Phase 2b Human Challenge study to determine if vaccination with BPZE1 prevents colonization from wild-type Bordetella pertussis infection.
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a vaccine company utilizing its B-Tech technology to develop novel vaccines against infectious diseases, today announced that multiple presentations and poster sessions reviewing data from Phase 2a and Phase 2b clinical trials of its lead pertussis vaccine candidate, BPZE1, are scheduled for the 13th International Bordetella Symposium to be held on June 26 – June 30, 2022 at the University of British Columbia.
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies today announced that the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) has selected ILiAD’s B-Tech Vector Technology for funding as part of its newly created Innovation for Tuberculosis Vaccine Discovery (ITVD) program. This program supports novel innovative vaccine candidates for the prevention of tuberculosis.
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, a late stage biotech development company focused on global eradication of disease due to Bordetella pertussis, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BPZE1, a next generation vaccine for active booster immunization against pertussis.
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies announces enrollment of the first participants in the SUPER Trial (Standing Up to PERtussis) – the first study in school-age children of BPZE1, a live attenuated intranasal pertussis vaccine. The SUPER Trial is a multicenter, randomized, placebo-controlled, and observer-blinded Phase 2b study in healthy school age children across 12 to 16 sites in the United Kingdom and Australia to assess the immunological response and safety profile of a single dose of BPZE1 with and without co-administration of BOOSTRIX®. Approximately 600 participants 6 to 16 years old will be randomly assigned to one of three study groups.